➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Merck
McKesson
Johnson and Johnson
Express Scripts

Last Updated: December 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Alisporivir

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Alisporivir?

Alisporivir is an investigational drug.

There have been 15 clinical trials for Alisporivir. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2011.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis A. The leading clinical trial sponsors are Debiopharm International SA, Parexel, and Assistance Publique - Hôpitaux de Paris.

There are three US patents protecting this investigational drug and eighty-two international patents.

Recent Clinical Trials for Alisporivir
TitleSponsorPhase
Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)Debiopharm International SAPhase 2
Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)Assistance Publique - Hôpitaux de ParisPhase 2
Two-way Interaction Between Alisporivir and EDP239Enanta PharmaceuticalsPhase 1

See all Alisporivir clinical trials

Clinical Trial Summary for Alisporivir

Top disease conditions for Alisporivir
Top clinical trial sponsors for Alisporivir

See all Alisporivir clinical trials

US Patents for Alisporivir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Alisporivir   Start Trial Methods for treating HCV AbbVie Inc. (North Chicago, IL)   Start Trial
Alisporivir   Start Trial Methods for treating HCV AbbVie Inc. (North Chicago, IL)   Start Trial
Alisporivir   Start Trial Process for the manufacture of cyclic undecapeptides Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Alisporivir

Drugname Country Document Number Estimated Expiration Related US Patent
Alisporivir Argentina AR088463 2031-10-21   Start Trial
Alisporivir Austria AT514003 2031-10-21   Start Trial
Alisporivir Australia AU2013201406 2031-10-21   Start Trial
Alisporivir Brazil BR112014006314 2031-10-21   Start Trial
Alisporivir Canada CA2811203 2031-10-21   Start Trial
Alisporivir Canada CA2851104 2031-10-21   Start Trial
Alisporivir Canada CA2886502 2031-10-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Merck
McKesson
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.